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INTRODUCTION: Localized excision combined with radiation and chemotherapy represents the current
standard of care for recurrent breast cancer. However, in certain conditions a forequarter amputation
may be employed for these patients.
PRESENTATION OF CASE: We present a patient with recurrent breast cancer who had a complicated treat-
ment history including multiple courses of chemotherapy, radiation, and local surgical excision. With
diminishing treatment options, she opted for a forequarter amputation in an attempt to limit the spread
of cancer.
DISCUSSION: In our patient the forequarter amputation was utilized as a last resort to slow disease
progression after shehad failedmultiple rounds of chemotherapy and receivedmaximal radiation. Unfor-
tunately, while she had symptomatic relief in the short-term, she had cutaneous recurrence ofmetastatic
adenocarcinomawithin 2months of the procedure. In comparing this casewith other reported forequar-
ter amputations, patients with non-metastatic disease showed a mean survival of approximately two
years. Furthermore, among patients who had signiﬁcant pain prior to surgery, all patients reported pain
relief, indicating a signiﬁcant palliative beneﬁt. This seems to indicate that our patient’s unfortunate out-
comewas anomalous compared to that ofmost patients undergoing forequarter amputation for recurrent
breast cancer.
CONCLUSION: Forequarter amputation can be judiciously used for patients with recurrent or metastatic
breast cancer. Patients with recurrent disease without evidence of distant metastasesmay be considered
for curative amputation,while othersmay receive palliative beneﬁt; disappointingly our patient achieved
neither of these outcomes. In the long term, these patients may still have signiﬁcant psychological
problems.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Historically, forequarter amputations have been used for man-
agement of bone and soft-tissue sarcomas of the shoulder girdle,
although more recently it has been employed in the treatment
and palliation of recurrent breast cancer. Axillary tumor recur-
rence can be very problematic for patients, causing signiﬁcant
pain, lymphedema, limb dysfunction, and/or skin ulceration. In
cases of isolated recurrence, management using localized surgery,
chemotherapy, and radiation is the preferred approach. However,
Abbreviations: ALND, axillary lymph node dissection; BCT, breast con-
serving therapy; CA, cancer antigen; ER, estrogen receptor; MRA, magnetic
resonance angiography; OR, operating room; PET/CT, positron emission tomog-
raphy/computed tomography; PR, progesterone receptor; RT, radiotherapy; SLN,
sentinel lymph nodes.
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for patients who have more signiﬁcant invasion without the pos-
sibility of local excision, a radical approach may be necessary for
removal of the tumor in those patients desiring aggressive onco-
logic treatment. In these cases, the forequarter amputation offers
the possibility of stopping the spread of the tumor while also palli-
ating the pain andothermorbidities often associatedwith invasion.
We report the case of a forequarter amputation attempting to pal-
liate a patient for axillary recurrence of breast cancer and provide
a review of the literature on this controversial subject.
2. Presentation of case
A49-year-oldwomanpresented toour institutionwith ahistory
of recurrent breast cancer. On her initial presentation two years
earlier, she detected a mass in her right breast and presented to
her primary care physician for further work-up. Prior surgical his-
tory included a gastric bypass but no breast-related procedures.
The family history was signiﬁcant for bilateral breast cancer in her
mother. The patient was on no medications and was otherwise
healthy. Thephysical examinationdetected amobile, palpable, ﬁrm
http://dx.doi.org/10.1016/j.ijscr.2015.04.018
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (A) Horizontal sections on PET/CT indicating axillary recurrence of the cancer prior to surgery, and (B) post-surgical scan indicating removal of the affected lymph
nodes and subsequent reduction in PET/CT signal.
mass in the central right breast. No worrisome lymphadenopathy
was appreciated. Mammography detected a probable right-sided
breast cancer.
An ultrasound-guided ﬁne needle aspiration identiﬁed an inva-
sive ductal carcinoma, and the patientwas advised to have surgery.
The patient opted for a right simple mastectomy to remove the
2.5 cmmass;marginswere free. Two axillary sentinel lymph nodes
(SLN) were negative. Themass was a Nottingham grade III invasive
ductal carcinoma that was estrogen receptor (ER), progesterone
receptor (PR), andHER-2/neunegative (triple negative). The nipple,
skin, and chest wall were free of involvement. She was subse-
quently treated with dose-dense adjuvant chemotherapy using
Adriamycin and cyclophosphamide for four cycles followed by four
cycles of Taxol given every two weeks followed by external beam
radiation to the chest wall and lower right axilla (50Gy in 25 frac-
tions).
Despite a negative BRCA genotype, the patient sought aggres-
sive management of her oncologic risks and underwent bilateral
oophorectomy for known polycystic ovaries and a rising cancer
antigen (CA) 125 level. She was ﬁt and seemingly well for one year.
Thirteenmonths after the simplemastectomy and SNL removal,
she noticed right axillary lymphadenopathy which was conﬁrmed
by positron emission tomography/computerized tomography
(PET/CT) as shown in Fig. 1A. There was no evidence of systemic
metastatic disease. A ﬁne-needle aspiration indicated this was
metastatic poorly differentiated adenocarcinoma, and subsequent
axillary dissection found 2 of 10 lymph nodes involved with tumor
(Fig. 1B indicates PET/CT following axillary dissection). Postopera-
tively the patient received an additional 50Gy of radiation to the
axilla. She started adjuvant chemotherapy with gemcitabine and
carboplatin, completing ﬁve cycles over the next ﬁve months.
A month after conclusion of her chemotherapy a PET scan indi-
cated some nonspeciﬁc uptake in the right axilla, but no treatment
was recommended at that time. Six months later, there was a pal-
pable, ﬁrm node in the right axilla. An ultrasound-guided biopsy
revealedmetastatic adenocarcinoma. At this time, shewas referred
to our institution.
Withconcerns radiationwasno longeranoption, thepatientand
her oncologists desired lymph node removal in hopes of analysis
to devise a better chemotherapy regimen. With a full understand-
ing that more surgery would unlikely be curative, the patient and
surgeonagreedona third axillary operation; theprocedurewasdif-
ﬁcult with dense, irradiated scar tissue throughout the axilla (Fig. 2
shows the intraoperative ultrasound). The node and surrounding
tissue was removed en bloc, but resection of the axillary vein and
pectoralis muscle was avoided. Histologic analysis revealed poorly
differentiated adenocarcinoma involving the lymph node consis-
tentwith aprimarybreast source.Magnetic resonance angiography
(MRA) performed three months later showed an ill-deﬁned 4.5 cm
soft tissue mass in the right axilla consistent with recurrent tumor
or adenopathy and possible involvement of the axillary vein and
chest wall (Fig. 3). At this time there was no evidence of distant
metastatic disease. In consultingwithhermedical team, thepatient
was presented the options of continuing with observation, further
chemotherapy, or a forequarter amputation. In order to attempt
a more aggressive solution to the issue, the patient opted for a
Fig. 2. Intraoperative ultrasound of the axilla indicating dense, woody tissue with
diffuse scarring from radiation therapy.
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Fig. 3. (A) Coronal MRA showing axillary recurrence of a 4.5 cmmass abutting the chest wall and axillary vein with possible involvement; (B) and (C) demonstrate the tumor
in horizontal sections.
Fig. 4. Photographs during the surgical procedure showing removal of the right arm, resection of the chest wall between ribs 2–5, resection of a lung nodule, placement of a
brachial plexus nerve catheter, and chest wall reconstruction.
forequarter amputation, which was successfully performed one
month later. The surgery involved removal of the right arm, resec-
tion of the chest wall from ribs 2–5, wedge resection of a 1mm
right lung nodule (palpated during surgery but not seen on imag-
ing), chest wall reconstruction, and placement of a right brachial
plexus nerve catheter (Fig. 4). The total OR time was 4.5h. Histol-
ogy revealed that the axillary mass and pulmonary nodule were
both consistent with poorly differentiated adenocarcinoma with a
primary breast source; surgical resection margins were negative.
Her postoperative course was generally uneventful save for a brief
episode of atrial ﬁbrillation. The patient was discharged on post-
operative day 7 with referrals to physical therapy, occupational
therapy, and amputee service, as well as deep vein thrombosis
prophylaxis with acetylsalicylic acid for six weeks.
At sixweek follow-up, the patient had developed new skin nod-
ules on the chest surrounding the surgical site. Biopsy of these
nodules was positive for ER/PR negative metastatic undifferenti-
ated adenocarcinoma. Additionally, a PET scan showed that there
was now left axillary lymphadenopathy measuring 2 cm in diam-
eter. She thus underwent three full cycles of eribulin treatment.
In the following months she was treated with further palliative
radiation and weekly cisplatin chemotherapy. Unfortunately, this
patient went on to suffer from further metastases to the lung
with deterioration of her health and consistent phantom pain. She
was also hospitalized multiple times for severe polymicrobial skin
ulcerations until her eventual passing several months later.
3. Discussion
Breast cancer represents the most common form of cancer
among women in the United States. The 5-year relative survival of
individuals with breast cancer in 2009was reported to be 98.6% for
thosewith localized breast cancer at diagnosis, 84.4%with regional
spread, and 24.3%with distantmetastasis [1]. Since the early 1990s,
the death rates have declined with the addition of new therapies
and earlier detection [2].
For patients who underwent a mastectomy as initial treatment
there is a 5–10% local recurrence rate within 10 years, although
up to 36% of patients with local recurrence may have simultane-
ous distant metastases [3–5]. For recurrence following BCT and RT,
mastectomy is the standard approach given there is no evidence
of distant metastasis; however, palliative mastectomy may still
be performed [6,7]. When axillary recurrence occurs, it has been
shown that multimodal treatment involving surgery, irradiation
and chemotherapy is the best approach to optimize disease-free
survival [8].
In the case of our patient, having received themaximumamount
of radiation and in an attempt to prevent further spread, radical
excision was performed using a forequarter amputation.While the
axillary recurrence had not caused any symptoms of pain or dys-
function yet, palliating these problems as well as delaying further
spread and recurrence made the forequarter amputation a more
viable option in the eyes of the patient.
The usage of forequarter amputation for recurrent breast cancer
is a rare practice, and Table 1 provides a summary of the outcomes
from published cases [9–20]. When patients sought surgery for
curative beneﬁt, they generally had good survival outcomes from
the procedure. For those who had locally recurrent cancer, 5 out
of 9 survived to the time of published data with an average sur-
vival among all patients of 23.4±14.6 months. While this is not
enough to determine that patients with locally recurrent breast
cancer will universally beneﬁt from a forequarter amputation, it
provides better context for its usage. Meanwhile, patients who
sought palliative therapy had a mean survival of 13±8.1 months if
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Table 1
Meta-analysis of patients who have undergone forequarter amputation for breast
cancer recurrence [9–20].
Patients (%)
Total number of cases 28 (100%)
Female 27 (96%)
Age 56.6±10.6 years
Pre-surgical diagnosis
Local recurrence only 16 (57%)
Conﬁrmed metastasis 12 (43%)
Presenting symptoms
Pain 15 (71%)
Edema 12 (57%)
Limb dysfunction 11 (52%)
Ulceration 10 (48%)
Infection 4 (19%)
Bleeding 3 (14%)
Fungation 1 (5%)
Necrosis 1 (5%)
Blistering 1 (5%)
Wound care 1 (5%)
No symptoms 1 (5%)
Intention of surgery (n=28)
Palliative 18 (64%)
Curative 10 (36%)
Surgical complications (n=19)
Flap necrosis 4 (21%)
Delayed healing 1 (5%)
Pleural effusion 1 (5%)
Pain relief (n=15) 15 (100%)
Survival
Alive Mean survival
Recurrent, palliative (n=7) 1 (14%) 13±8.1 mos.
Recurrent, curative (n=9) 5 (56%) 23.4±14.6 mos.
Metastatic, palliative (n=11) 0 (0%) 13.3±16.3 mos.
Metastatic, curative (n=1) 1 (100%) 23 mos.
they had local recurrence and 13.3±16.3 months with metastatic
disease.
Upon initial presentation, the most common symptoms among
patients included pain (71%), edema (57%), limb dysfunction (52%),
and ulceration (48%). In patients who noted pain as a presenting
symptom, 100% reported relief following the procedure. Fur-
thermore, immediate post-surgical complications were relatively
limited, with 4 patients (21%) experiencing ﬂap necrosis and only
1 patient each (5.3%) having problems with pleural effusion and
delayed healing. As a result, there can be palliative beneﬁt from
this surgery with seemingly limited post-operative complications.
Our patient lacked any real issues with pain or limb dysfunc-
tion as noted in patients in other studies and unfortunately did not
garner beneﬁt from this procedure because of early recurrence and
progressionofher cancer.Wehope thatherexperiencewasatypical
given thatmany of the patientswho underwent this procedure had
a much longer survival and received palliative beneﬁt long-term.
4. Conclusion
As suggested by previous authors, we would concur that there
are certain curative and palliative uses for the forequarter ampu-
tation with careful consideration. Our relatively asymptomatic
patient appreciated the efforts to eradicate her local tumor recur-
rence, but she did not gain long term beneﬁts. Patients who have
immobile, unresectable recurrent tumors in the axilla, with severe
pain with loss of function, are negative for distant metastasis,
and have any tumor-related complications including bleeding,
infection, or edema can be considered for curative forequarter
amputation. Palliatively, forequarter amputations can be used as
salvage therapy in patients with advanced axillary recurrence of
breast cancer and intractable pain [11–14,16].
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